Methyl-2-cyano-4-methyl-pent-4-enoat | 1453-48-1

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: Methyl-2-cyano-4-methyl-pent-4-enoat
• 英文别名: 2-Cyan-4-methyl-pent-4-en-saeure-methylester；Methyl 2-cyano-4-methylpent-4-enoate；methyl 2-cyano-4-methylpent-4-enoate
• CAS: 1453-48-1
• 化学式: C₈H₁₁NO₂
• 分子量: 153.181
• InChiKey: ACHHVWJWRUDCAG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  50.1
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  Methyl-2,2-dimethyl-1-cyano-cyclopropan-carboxylat 生成 Methyl-2-cyano-4-methyl-pent-4-enoat
  参考文献：
  名称：

  吡唑啉：IV。4,4-二烷基-3-氰基-3-甲氧基-Δ1-吡唑啉热解过程中烷基的重排

  摘要：

  已经合成了许多 4,4-二烷基-3-氰基-3-碳甲氧基-Δ1-吡唑啉。这些吡唑啉的热解产生环丙烷和烯烃产物。通过从吡唑啉系统的 C4 到 C5 的烷基重排形成烯烃产物表明在过渡态的 C5 上产生了正电荷。热解速率在极性溶剂中比在非极性溶剂中快这一事实也表明了过渡态的离子特性。

  DOI：

  10.1139/v65-188

文献信息

• PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE
  申请人：Castelhano Arlindo

  公开号：US20080261943A1

  公开（公告）日：2008-10-23

  The subject invention provides compounds having the structure: wherein, R 1 is a substituted or unsubstituted alkyl, wherein the substituent is hydroxyl, dihydroxy, carboxyl, —C(═O)NR a R b , —NR a R b , —NR a C(═O)NR a R b , —NR a C(═O)OR a , —OC(═O)NR a R b , or —NH C(═O) R a ; R 2 is hydrogen or a substituted or unsubstituted alkyl, wherein the substituent is hydroxyl, dihydroxy, carboxyl, —C(═O)NR a R b , —NR a R b , —NR a C(═O)NR a R b , —NR a C(═O)OR a , —OC(═O)NR a R b , or —NHC(═O)R a , or R 1 , R 2 and N together form a substituted piperazine, substituted azetidine ring, or a pyrrolidine ring substituted with —(CH 2 ) 2 OH or —CH 2 C(═O)OH; R 3 is a substituted or unsubstituted phenyl or a 5-6 membered heteroaryl ring, wherein the substituent is halogen, hydroxyl, cyano, (C 1 -C 15 )alkyl, (C 1 -C 15 )alkoxy, or —NR a R b ; R 4 is hydrogen or substituted or unsubstituted (C 1 -C 15 )alkyl; R 5 is —(CH 2 ) m OR 6 , —CHNOR 7 , —C(═O)NR 8 R 9 , —(CH 2 ) m C(═O)OR 10 , —(CH 2 ) k C(═O)NR 11 R 12 ; wherein R 6 is a substituted or unsubstituted (C 1 -C 30 )alkyl, (C 3 -C 10 )cycloalkyl, or an aryl, heteroaryl or 4-8 membered heterocyclic ring; R 7 is hydrogen, or a substituted or unsubstituted (C 1 -C 30 )alkyl, (C 1 -C 30 )alkylaryl; R 8 and R 9 are each independently hydrogen, or a substituted or unsubstituted (C 1 -C 30 )alkyl, (C 1 -C 30 )alkylaryl, (C 1 -C 30 )alkylamino, (C 1 -C 30 )alkoxy, or a saturated or unsaturated, monocyclic or bicyclic, carbocyclic or heterocyclic ring, or R 8 , N, and R 9 together form a substituted or unsubstituted 4-8 membered heterocyclic ring; R 10 is hydrogen or a substituted or unsubstituted (C 1 -C 30 )alkyl, (C 3 -C 10 )cycloalkyl, or an aryl, heteroaryl or heterocyclic ring; R 11 , N and R 12 together form a 4-8 membered heterocyclic ring; R a and R b are each independently hydrogen or alkyl; m is 0, 1, 2 or 3; and k is 1, 2 or 3, or a specific enantiomer thereof, or a specific tautomer thereof, or a pharmaceutically acceptable salt thereof, and a method for treating a disease associated with the A 2b adenosine receptor in a subject in need of such treatment comprising administering to the subject a therapeutically effective amount of the compounds of the invention.

  本发明提供了具有以下结构的化合物：其中，R1是取代或未取代的烷基，其中取代基是羟基，二羟基，羧基，—C（═O）NRaRb，—NRaRb，—NRaC（═O）NRaRb，—NRaC（═O）ORa，—OC（═O）NRaRb或—NH C（═O） Ra；R2是氢或取代或未取代的烷基，其中取代基是羟基，二羟基，羧基，—C（═O）NRaRb，—NRaRb，—NRaC（═O）NRaRb，—NRaC（═O）ORa，—OC（═O）NRaRb或—NHC（═O）Ra，或R1，R2和N共同形成取代的哌嗪，取代的氮杂环丙烷环或取代的吡咯烷环，取代基为—（CH2）2OH或—CH2C（═O）OH；R3是取代或未取代的苯基或5-6成员的杂芳基环，其中取代基为卤素，羟基，氰基，（C1-C15）烷基，（C1-C15）烷氧基或—NRaRb；R4是氢或取代或未取代的（C1-C15）烷基；R5是—（CH2）mOR6，—CHNOR7，—C（═O）NR8R9，—（CH2）mC（═O）OR10，—（CH2）kC（═O）NR11R12；其中，R6是取代或未取代的（C1-C30）烷基，（C3-C10）环烷基或芳基，杂芳基或4-8成员的杂环；R7是氢或取代或未取代的（C1-C30）烷基，（C1-C30）烷基芳基；R8和R9各自独立地是氢或取代或未取代的（C1-C30）烷基，（C1-C30）烷基芳基，（C1-C30）烷基氨基，（C1-C30）烷氧基或饱和或不饱和的单环或双环，碳环或杂环，或R8，N和R9共同形成取代或未取代的4-8成员的杂环；R10是氢或取代或未取代的（C1-C30）烷基，（C3-C10）环烷基，芳基，杂芳基或杂环；R11，N和R12共同形成4-8成员的杂环；Ra和Rb各自独立地是氢或烷基；m为0，1，2或3；k为1，2或3，或其特定对映体，或其特定互变异构体，或其药学上可接受的盐，以及一种用于治疗与A2b腺苷受体相关的疾病的方法，包括向需要这种治疗的受体中施用本发明化合物的治疗有效量。
• McGreer,D.E. et al., Proceedings of the Chemical Society, London, 1964, p. 415
  作者：McGreer,D.E. et al.

  DOI：——

  日期：——
• US7645754B2
  申请人：——

  公开号：US7645754B2

  公开（公告）日：2010-01-12
• PYRAZOLINES: IV. REARRANGEMENT OF ALKYL GROUPS DURING THE PYROLYSIS OF 4,4-DIALKYL-3-CYANO-3-CARBOMETHOXY-Δ¹-PYRAZOLINES
  作者：Donald E. McGreer、Robert S. McDaniel、Magnus G. Vinje

  DOI：10.1139/v65-188

  日期：1965.5.1

  of 4,4-dialkyl-3-cyano-3-carbomethoxy-Δ1-pyrazolines have been synthesized. Pyrolysis of these pyrazolines yielded cyclopropane and olefin products. The formation of olefin products by rearrangement of an alkyl group from C4 to C5 of the pyrazoline system suggests that positive charge is developed on C5 in the transition state. Ionic character in the transition state was also indicated by the fact that

  已经合成了许多 4,4-二烷基-3-氰基-3-碳甲氧基-Δ1-吡唑啉。这些吡唑啉的热解产生环丙烷和烯烃产物。通过从吡唑啉系统的 C4 到 C5 的烷基重排形成烯烃产物表明在过渡态的 C5 上产生了正电荷。热解速率在极性溶剂中比在非极性溶剂中快这一事实也表明了过渡态的离子特性。